SEBI has declared the Grade A Phase 1 Result 2026 on its official website. Shortlisted candidates will appear for the Phase 2 exam scheduled on 21 February 2026.
-- Unprecedented data from FORTITUDE™ dose escalation cohorts for del-brax treated participants, compared to placebo, demonstrate improvement in function, strength and PROs as well as rapid and ...
Pyxis Oncology announces Phase 1/2 trials for PYX-201, combining it with KEYTRUDA® to treat advanced solid tumors. Pyxis Oncology, Inc. has announced the initiation of two significant clinical trials ...
The Securities and Exchange Board of India (SEBI) is likely to release the SEBI Grade A Phase 1 Result 2026 shortly on its official website. The Phase 1 exam for the post of Officer Grade A (Assistant ...
Tividenofusp alfa treatment showed reduction and normalization in key disease biomarkers, stabilization or improvement in clinical endpoints including adaptive behavior, cognition and hearing, and ...
Novo Nordisk (NVO) has released full data from a Phase 1b/2a trial for its novel obesity drug, amycretin noting that the injectable, designed to target GLP-1 and amylin receptors, caused up to 24% of ...
ATR04-484 is a live biotherapeutic product targeting EGFR inhibitor-associated rashes in cancer patients, containing a modified Staphylococcus epidermidis strain. EGFR inhibitors, used in treating ...
Phase 2 cohort-2 trial in progress: Vabametkib plus lazertinib for patients with EGFR-mutant NSCLC who developed resistance to 1st-line, 3rd-gen-EGFR TKIs via C-Met dysregulation. A randomized phase 3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results